News

Mr Hartnett joins Tepha following an 18 year career with Boston Scientific during which he progressed from field sales, to marketing management, and, most recently, to strategic planning

This newly identified lead is said to be the first from a program being evaluated as a potential treatment for pain and the fifth lead identified since the

Michael Crowley, vice president of business development at PharmaForm, said: “We are very pleased to have been awarded this important contract and with our long relationship with Repros.

The data showed a decrease of 0.02ml in end systolic volume (0.13ml to 0.11ml) and a 38% increase in stroke volume (0.31 ml to 0.43 ml) from three

The co-exclusive agreement continues to cover all of the cardiology and drugs of abuse rapid test products manufactured by the Biosite subsidiary of Inverness and sold under the

Moffitt is the seventh center in this multi-center trial using the Delcath System. Delcath and Moffitt have entered into a clinical research agreement to conduct the Phase III

Following the special clinical protocol assessment process with the FDA and a formal scientific advice meeting with the Committee for Human Medicinal Products of the European Medicines Agency

The Phase IIa study is designed to assess the safety and efficacy of 1% Xoma 629 topical gel compared to a control cream indicated for impetigo. The clinical

The financing was led by X Gen, a family venture fund based in Cleveland, Ohio. It also includes a grant from the Cleveland Clinic Global Cardiovascular Innovation Center